Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Genprex, Inc. (GNPX)

1.32   0.03 (2.33%) 11-28 09:36
Open: 1.3 Pre. Close: 1.29
High: 1.32 Low: 1.3099
Volume: 5,060 Market Cap: 63(M)

Technical analysis

as of: 2022-11-28 9:18:54 AM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.61     One year: 1.71
Support: Support1: 1.25    Support2: 1.03
Resistance: Resistance1: 1.38    Resistance2: 1.47
Pivot: 1.31
Moving Average: MA(5): 1.28     MA(20): 1.32
MA(100): 1.49     MA(250): 1.68
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 15.8     %D(3): 10
RSI: RSI(14): 44.3
52-week: High: 3.61  Low: 1.16
Average Vol(K): 3-Month: 104 (K)  10-Days: 70 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GNPX ] has closed above bottom band by 33.6%. Bollinger Bands are 58.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.32 - 1.33 1.33 - 1.34
Low: 1.27 - 1.28 1.28 - 1.29
Close: 1.28 - 1.29 1.29 - 1.3

Company Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Headline News

Mon, 28 Nov 2022
Genprex : Material Agreement - Form 8-K -

Wed, 12 Oct 2022
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Tue, 16 Aug 2022
Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers - Yahoo Finance

Thu, 05 May 2022
Genprex Issues Shareholder Letter and Provides 2022 Corporate Update - PR Newswire

Wed, 02 Mar 2022
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer - BioSpace

Mon, 03 Jan 2022
8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVE - InvestorPlace

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 48 (M)
Shares Float 47 (M)
% Held by Insiders 1.3 (%)
% Held by Institutions 9.4 (%)
Shares Short 1,580 (K)
Shares Short P.Month 1,750 (K)

Stock Financials

EPS -0.4
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.56
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -37.2
Return on Equity (ttm) -62.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.48
Qtrly Earnings Growth 0
Operating Cash Flow -16 (M)
Levered Free Cash Flow -6 (M)

Stock Valuations

PE Ratio -3.27
PEG Ratio 0
Price to Book value 2.26
Price to Sales 0
Price to Cash Flow -3.78

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.